港股異動 | 藥明生物(2269.HK)漲近4%領漲藍籌股 終止由歷史高位九連跌
格隆匯9月11日丨本週一起正式“染藍”的藥明生物(2269.HK)終止由歷史高位九連跌,現漲近4%領漲恆指成份股,報185.1港元。美銀證券發研報指,疫情下藥明生物上半年業績仍帶來驚喜,保持強勁增長,產能利用率提高推動利潤提升。該行將2020至2022年每股盈利預測提升至1.37、2.07及3.04元人民幣,目標價由116港元調高至200港元,並重申“買入”評級。瑞銀髮表報告指,雖然業務環境艱難,但藥明生物(2269.HK)在今年上半年仍簽署了38個新項目(早前指引為20個),令集團上半年收入及純利表現均優於預期。該行上調藥明生物股份目標價,由167港元升至227港元,維持“買入”評級

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.